Evidence map›Paper›PMID 38934499›Full record

ArticleHuman vaccines & immunotherapeutics2024

Characterization of neutralizing chimeric heavy-chain antibodies against tetanus toxin.

Kexuan Cheng, Jiansheng Lu, Jiazheng Guo, Rong Wang, Lei Chen, Xi Wang, Yujia Jiang, Yating Li, Changyan Xu, Qinglin Kang and 6 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Kexuan ChengDepartment of Occupational Health and Occupational Diseases, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China.
Jiansheng LuLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Jiazheng GuoLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Rong WangLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Lei ChenLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Xi WangLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Yujia JiangLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Yating LiDepartment of Occupational Health and Occupational Diseases, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China.
Changyan XuDepartment of Occupational Health and Occupational Diseases, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China.
Qinglin KangLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Gulisaina QiaerxieLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Peng DuLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Chen GaoLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Yunzhou YuLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Zhixin YangLaboratory of Advanced Biotechnology, Beijing Institute of Biotechnology, Beijing, China.
Wei WangDepartment of Occupational Health and Occupational Diseases, College of Public Health, Zhengzhou University, Zhengzhou, Henan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Tetanus toxin (TeNT) is one of the most toxic proteins. Neutralizing antibodies against TeNT are effective in prevention and treatment. In this study, 14 anti-tetanus nanobodies were obtained from a phage display nanobody library by immunizing a camel with the C-terminal receptor-binding domain of TeNT (TeNT-Hc) as the antigen. After fusion with the human Fc fragment, 11 chimeric heavy-chain antibodies demonstrated nanomolar binding toward TeNT-Hc. The results of toxin neutralization experiments showed that T83-7, T83-8, and T83-13 completely protected mice against 20 × the median lethal dose (LD

Indexed as

Antibodies, NeutralizingImmunoglobulin Heavy ChainsSingle-Domain AntibodiesTetanusTetanus ToxinAnimalsAntibodies, BacterialCamelusFemaleHumansMiceMice, Inbred BALB CAntibodies, BacterialAntibodies, NeutralizingImmunoglobulin Heavy ChainsSingle-Domain AntibodiesTetanus Toxinheavy chain antibodynanobodyneutralizing antibodyphage display libraryTetanus toxin

Identifiers

PMID38934499
PMCPMC11212558

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.